baber/WOPTO huggingface dataset:
Patent NZ-529802-A (NZ)
Title: Monitoring method and system
Inventor: ROBERTS VERNE WALTER
IPC: G01R31/02
Filed: 2003-11-26
Abstract: Transducers associated with an electric fence energiser 8 produce a set of data signals, indicative of the performance parameters of the energiser, on the lines 2, which are fed, optionally via filters 5, to the processor 6. The data signals are stored in a circular buffer storage 3 to provide a history of the performance of the energiser. The data signals stored in the buffer 3 may be accessed by a computer 9 via an output line. If an input signal exceeds a predetermined level this causes the associated comparator 5 to flag the processor which then issues a count signal to an appropriate event counter 4. The respective counts can also be monitored by the computer 9.
Patent NZ-530845-A (NZ)
Title: Composition for topical administration
Inventor: UENO RYUJI
IPC: A61K31/535
Filed: 2002-07-02
Abstract: An interleukin 2 inhibitor and an antimicrobial agent can be used for manufacturing a composition for topical administration for the treatment of inflammation and/or infections. Preferably the IL-2 inhibitor is a macrolide compound or cyclosporine, such as F502, and the antimicrobial agent is a quinolone antimicrobial agent, such as ofloxacin.
Patent NZ-530853-A (NZ)
Title: Polyolefin film, tape or yarn
Inventor: LOOS JOACHIM
IPC: D01D5/253
Filed: 2002-07-19
Abstract: A monoaxially drawn polyolefin multilayer film, tape or yarn of the AB or ABA type is disclosed, which has a total stretch ratio of more than 12, and an E-modulus of at least 10GPa, substantially consisting of a central layer (B) of a polyolefin selected from polyethylene and polypropylene, and one or two other layers (A) of a polyolefin from the same class as the material of the central layer B, the DSC melting point of the material of the said other layers (A) being lower than the DSC melting point of the material of the said central layer (B), wherein the central layer (B) is between 50 and 99 wt.% of the material and the other layers (A) between 1 and 50 wt.%. A method of manufacturing such a tape, film or yarn is also disclosed.
Patent NZ-531107-A (NZ)
Title: Plant disease/pest resistance and defence response facilitated with chitinases from Lolium species
Inventor: SPANGENBERG GERMAN
IPC: C12N15/29
Filed: 2004-02-11
Abstract: Described are nucleic acids and nucleic acid fragments encoding amino acid sequences for chitinases in plants and the use thereof for modification of plant defence response, disease and/or pest resistance, manipulation of chitin breakdown, production of signals and elicitors for the manipulation of plant development, and/or host defence reaction in plants.
Patent NZ-534956-A (NZ)
Title: Pre- and post-treatment system and method for periphyton filtration using ozone
Inventor: JENSEN KYLE R
IPC: C02F9/00
Filed: 2003-02-28
Abstract: A method of treating water is comprised of exposing the water influent comprising water to ozone in sufficient quantity to disrupt the cell walls of undesired micro-organisms, thereby releasing nutrients from within the micro-organisms in a form amenable to bioassimilation, the ozone being provided in sufficient quantity to oxidize toxic, humic and tannic compounds to a form amenable to bioassimilation. The method also includes contacting aquatic plants with the ozone-exposed water where by the aquatic plants mediate the removal of the released and oxidized nutrients.
Patent NZ-536736-A (NZ)
Title: Non-nucleoside reverse transcriptase inhibitors
Inventor: SIMONEAU BRUNO
IPC: A61P31/18
Filed: 2003-05-14
Abstract: Disclosed are compounds of formula I, wherein; R2 is H, alkly, halo, haloalkyl, OH, alkoxy, NH-alkyl or N(alkyl)2, R4 is H or Me, R5 is H or Me, R11 is H, alkyl, cycloalkyl or alkly-cycloalkyl, A is an alkyl connecting chain, B is O or S, Ring C is an optionally substituted 6- or 10- membered aryl or a 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N and S, and Ring D is an optionally substituted 6- or 10-membered aryl or 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N and S. The compounds are used for the manufacture of medicaments for the treatment or prevention of HIV infection.
Patent NZ-539418-A (NZ)
Title: Overflow and drain control for a bathtub
Inventor: SWART PETER W
IPC: E03C1/232
Filed: 2003-09-15
Abstract: Disclosed is a bathtub drain arrangement for implementation in a soaker bathtub of the type having a main basin coupled to a surrounding overflow trough. There is a drain channel extending from under the trough. There is also a drain pipe for draining water from the main basin. A drain control is positioned in the trough to extend into the drain channel and then outward there from.
Patent NZ-541399-A (NZ)
Title: Cutter assembly for extruding shaped food pieces
Inventor: HUNTER THOMAS B
IPC: A21C11/16
Filed: 2003-12-23
Abstract: A cutter assembly (1) for an extruder includes an elongated extrusion member (9) having an opened feed end (12). The opened feed end is attachable in fluid communication with a first manifold of the extruder. A filling tube (20) extends through the elongated extrusion member, which is attachable to a second manifold of the extruder. An extrusion die (11) is formed in the elongated extrusion member. The extrusion die is shaped to the general shape of a natural food piece. A cutter member (14) is reciprocally slidable on the extrusion wall (10) and has cutting surface (35) shaped to the general shape of the extrusion die for cutting extrudate to a desired length as the extrudate exits the die.
Patent NZ-541944-A (NZ)
Title: 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
Inventor: PUSCHL ASK
IPC: A61K31/4409
Filed: 2004-04-02
Abstract: Disclosed is a serotonin reuptake inhibitor of formula (I) wherein the substituents are defined in the specification. The compounds are useful in the treatment of affective disorder, including depression, anxiety disorders including general disorder and panic disorder and obsessive compulsive disorder.
Patent NZ-542959-A (NZ)
Title: Building element with varying surface characteristics made from sheet formed into special profiles, typically for fencing posts and rails
Inventor: MANN RONALD LESLIE
IPC: E04H17/14
Filed: 2004-03-17
Abstract: A building element (10) is formed from sheet material having opposite major surfaces (11, 12) that extend between longitudinal edges (13, 14). Margins of the sheet adjacent the longitudinal edges are turned out of a mid-plane of the sheet to form opposite profiled sections (16 and 17). The major surfaces (11, 12) of the building element have different surface characteristics, and one profiled section has one of the major surfaces as its outer surface, and the other profiled section has the other major surface as its outer surface.
Patent NZ-545653-A (NZ)
Title: Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Inventor: KOSITPRAPA UNCHALEE
IPC: A61K9/22
Filed: 2004-02-12
Abstract: Disclosed is a pharmaceutical dosage form having a first and second active drug, said dosage form comprising: a) a controlled release core comprising at least one pharmaceutically acceptable excipient and only one active drug that consists of metformin hydrochloride; and b) an immediate release thiazolidinedione derivative containing component, wherein not less than 85 wt% of the thiazolidinedione is released from the dosage form within 45 minutes when tested according to the United States Pharmacopoeia (USP) 26, with Apparatus 1 at 100 rpm, 37 degrees Celsius and 900 ml of 0.3 M KCl-HCl Buffer, pH 2.0, wherein the thiazolidinedione derivative can be either pioglitazone or a pharmaceutically acceptable salt thereof and after storage at 40 degrees Celsius and 75% relative humidity for three months, the total thiazolidinedione related compounds or impurities in the dosage form is not more than 0.6 wt% as determined by high performance liquid chromatography and each individual thiazolidinedione related compound or impurity in the final dosage form is not more than 0.25 wt%, and wherein the thiazolidinedione related compounds and impurities are as described in the specification.
Patent NZ-550599-A (NZ)
Title: Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
Inventor: BRIAND THIERRY
IPC: A61K31/506
Filed: 2005-05-12
Abstract: Crystalline forms A and B of 5-methyl-pyridine-2-sulfonic acid [6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide of formula (I) are disclosed, whereby form B is the most stable form. 5-methyl-pyridine-2-sulfonic acid [6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide also forms solvates with, for example, ethanol, acetone, tetrahydrofuran, methanol, isopropanol, 2-butanone and dichloromethane. Methods of preparing these crystals and solvates and pharmaceutical compositions comprising these crystals and solvates are also disclosed.
Patent NZ-551765-A (NZ)
Title: Equipment cabinet
Inventor: HILL DENNIS MASON
Filed: 2006-12-01
Abstract: An equipment cabinet is disclosed. The equipment cabinet comprises: (a) an inner compartment (3); (b) an outer compartment (5) enclosing the inner compartment (3); and (c) a ventilation system having at least one operating configuration which enables air to flow from outside the outer compartment (5) to the inner compartment (3) then to the outer compartment (5), and which enables little or no air to flow from the outer compartment (5) to the inner compartment (3).
Patent NZ-552761-A (NZ)
Title: Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
Inventor: MATSUOKA HIROHARU
IPC: C07D213/65
Filed: 2005-07-26
Abstract: Disclosed is a cyclohexane derivative represented by formula (I) wherein: A is -O-, -CH2-, or -NH-; n is an integer selected from 0 and 1; R6 and R7 are each independently a hydrogen atom or a C1 û C6 alkyl group m is an integer selected from 1 to 3; Q is selected from Q1 to Q5 represented by the following corresponding formulae: Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; A2 is optionally substituted aryl or optionally substituted heteroaryl, or a pharmaceutically acceptable salt. Also disclosed is a medicine, a medicinal composition each containing the compound for the treatment of diseases attributable to hyperglycaemia.
Patent NZ-561453-A (NZ)
Title: A linear sliding gate valve for a metallurgical vessel
Inventor: ROSE WILLIAM
IPC: B22D41/24
Filed: 2006-01-12
Abstract: A linear sliding gate valve 10 for a metallurgical vessel, comprising: a slide plate with a first orifice and a fixed plate 22 with a second orifice, a slideable tray 26 supporting the slide plate and arranged to slide the slide plate relative to the fixed plate 22 so as to control an outflow of the metallurgical vessel by the relative position of the first and second orifices , , the slide plate being rotatable relative to the slideable tray 26, and a ratchet mechanism 40, for providing defined angular positions of the slide plate, characterized in that the ratchet mechanism 40, is mounted on the slideable tray 26 such that the slideable tray 26 forms the fixed frame of the ratchet mechanism 40, .
Patent NZ-563386-A (NZ)
Title: Hinges
Inventor: DAWSON JOHN
IPC: E05D3/02
Filed: 2007-11-13
Abstract: Disclosed is a hinge assembly including a first leaf and a second leaf each with at least one sleeve, the second leaf being complementary to the first leaf. The hinge assembly further includes a hinge pin for insertion through the sleeves when aligned. At least one leaf is substantially plate-like with a general plate plane and at least one passageway through the plate plane. The passageway is coincident with and parallel to the plate plane and is suitable for receiving a fixing screw. The axis of the at least one passageway is offset from, but is substantially normal to the leafs sleeve axis. The general plate plane is substantially parallel to its leafs sleeve axis.
Patent NZ-566247-A (NZ)
Title: Free floating wave energy converter with flexible pipe connected to inflexible inlet pipe with bouyancy tank
Inventor: GHOUSE SYED MOHAMMED
IPC: F03B13/14
Filed: 2006-08-01
Abstract: A wave energy converter includes a flexible wave pipe 404 that floats on the water surface, following the wave form. The flexible pipe has no valves between the inlet end 403 and the outlet end. Slugs of water and air enter, one after the other, through the inlet 402 of an inflexible inlet pipe and then into the connected flexible wave pipe. A buoyancy tank 401 is attached to the inflexible inlet pipe to keep it afloat at an appropriate level so that the slugs of air 410 and water 413 are ingested synchronously with the waves passing the open inlet. Because the flexible pipe 404 conforms to the shape of the wave, the slugs of air and water are transported through the flexible pipe progressively converting wave energy to flow of fluids and pressure at the outlet end. The converter is moored to maintain a fore and aft axis along the flexible pipe generally facing the direction of the oncoming waves.
Patent NZ-569744-A (NZ)
Title: Volumetric dosing of components into dose package with in line check weighing
Inventor: DJURLE ALF
IPC: A61J3/07
Filed: 2007-01-22
Abstract: The respective first and second components, at least one of which is an active ingredient of a dose of a pharmaceutical product, are packaged into a dose package in a packaging machine by metering the volumes of the first and second components into the dose package, by weighing the metered volume of the first component on line between metering and packaging, and finally weighing the package and the components when packaged. By suitable processing of the weights the accuracy of the metering can be precisely determined and controlled.
Patent NZ-572741-A (NZ)
Title: Novel compound having affinity to amyloid for diagnosing Alzheimer's
Inventor: TANIFUJI SHIGEYUKI
IPC: C07F7/22
Filed: 2007-04-26
Abstract: Disclosed is a compound of formula (1), or a salt thereof, wherein A1-4 are each carbon or nitrogen, with at least one being carbon, R3 is -(O)n(CH2)mR1, wherein m is 0-4, n is 0-1, and R1 is as defined in the specification. The compound is disclosed to be a low-toxic diagnostic agent for Alzheimer's disease.
Patent NZ-586119-A (NZ)
Title: System for measuring, indicating and managing electricity consumption
Inventor: THOMAS RAJEEV
IPC: H02J3/14
Filed: 2008-11-11
Abstract: Disclosed is a remote controller (112) for demand side electrical load management. The remote controller (112) includes a plurality of electrical connections for supplying electricity to a plurality of remote loads (102.1, 102.2, 102.3), a plurality of electrical switches (114.1, 114.2, 114.3) associated with the electrical connections, at least one electricity measurement device for measuring electricity supplied to or consumed by each of the loads (102.1, 102.2, 102.3) and a communication arrangement. The communication arrangement is operable to send an indication message both to a master controller (122) and to a remote apparatus (104) for demand side management. The indication message indicates the electricity supplied to or consumed by the loads (102.1, 102.2, 102.3). The indication message may be used to display an indication of instantaneous energy consumption on the remote apparatus (104). The communication arrangement is also configured to send to the remote apparatus (104) a threshold message. The threshold message includes an indication of an electricity consumption threshold and an indication of a time period within which the consumer must limit their electricity consumption to comply with the electricity consumption threshold. The communication arrangement also receives from the master controller (122) an interrupt message indicating that electricity supply to at least one of the loads (102.1, 102.2, 102.3) is to be interrupted. The remote controller (112) is also operable to, in response to receipt of the interrupt message, toggle the switch (114.1, 114.2, 114.3) to each of the at least one load (102.1, 102.2, 102.3) to which electricity supply is to be interrupted. This allows remote interruption of the supply of electricity to the at least one load (102.1, 102.2, 102.3).
Patent NZ-586338-A (NZ)
Title: Bacterial compositions for the treatment of cancer
Inventor: GUNN HAROLD DAVID
IPC: A61K35/742
Filed: 2005-05-30
Abstract: Disclosed is the use of a preparation of whole killed bacteria of one or more pathogenic bacterial species in the manufacture of a medicament for preventing or treating a cancer located in a specific organ or tissue in a subject, wherein the preparation elicits an immune response in the subject, and wherein the pathogenic bacterial species is pathogenic in the corresponding specific organ or tissue in a healthy subject. .
Patent NZ-593392-A (NZ)
Title: Biomarker for detecting bladder cancer
Inventor: MORGAN RICHARD
IPC: C12Q1/68
Filed: 2009-12-21
Abstract: NZ 593392 Disclosed is a method for diagnosing bladder cancer in a patient or for identifying a patient at risk of developing bladder cancer, the method comprising: determining an amount of a cancer specific biomarker in a sample obtained from a patient; comparing the amount of the determined cancer specific biomarker in the sample from the patient to the amount of the cancer specific biomarker in a normal control; wherein the cancer specific biomarker comprises: a nucleic acid sequence comprising SEQ ID NO: 1, or a fragment, or a nucleic acid molecule which comprises said nucleic acid sequence; or an amino acid sequence comprising SEQ ID NO:2, or a fragment, or an amino acid molecule which comprises said amino acid sequence; and a difference in the amount of the cancer specific biomarker in the sample from the patient compared to the amount of the cancer specific biomarker in the normal control is associated with the presence of bladder cancer or is associated with a risk of developing bladder cancer.
Patent NZ-594185-A (NZ)
Title: Acoustic detection for respiratory treatment apparatus
Inventor: MARTIN DION CHARLES CHEWE
IPC: A61B5/08
Filed: 2010-02-10
Abstract: 594185 Disclosed is a method for detecting a respiratory treatment conduit obstruction. A sound sensor determines a measure of sound of a flow generator (110) within a respiratory treatment conduit and a processor analyses the measure of sound from the sound sensor. The processor then indicates a presence or absence of obstruction in the respiratory treatment conduit based on the analysing.
Patent NZ-604332-A (NZ)
Title: Power and telecommunications surge protection apparatus
Inventor: KULARATNA ALYTHWELA DOMINGO VITHANAYE NIHAL
IPC: H02H1/04
Filed: 2011-12-12
Abstract: 604322 Disclosed is a power surge protection apparatus within a surge protection circuit associated
Patent NZ-597794-A (NZ)
Title: Foot alignment tool
Inventor: SMITH NEIL ROBERT
IPC: A43B7/14
Filed: 2009-07-16
Abstract: A foot alignment tool is configured for aligning a foot bearing a load. The tool extends between a handle at one end and a support lever at an opposing end and is characterised in that the support lever is configured to be received under or substantially under the medial longitudinal arch or the cuboid of the foot and configured to be rotated so as translate and/or rotate the foot from the inside of the foot to the outside of the foot or from the outside of the foot to the inside of the foot by a predetermined amount about a foot heel-toe axis wherein the support lever is configured to apply a predetermined torque.
Patent NZ-598747-A (NZ)
Title: Androgen receptor modulating compounds
Inventor: WOHLFAHRT GERD
IPC: A61K31/416
Filed: 2010-10-27
Abstract: 598747 Compounds of formula (I) wherein R1 to R16, A. B and E are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.
Patent NZ-599908-A (NZ)
Title: Method and apparatus for supporting mismatch detection
Inventor: DING ZHEMIN
IPC: H04L45/24
Filed: 2010-11-25
Abstract: 599908 Disclosed is a method for service instance management in a first network node (2, 3) of a communication network (1). A plurality of bidirectional and distinct network paths (7, 8) for carrying a number of service instances (10a, 10b, 10c,) from the first network node to a second network node (2, 3) are monitored. A number of the network paths (7, 8) form a protection group associated with a respective service instance or group of service instances (10a, 10b, 10c). The monitoring includes continuously and periodically sending Continuity Check Messages, CCMs (11), on a monitored network path (7, 8) to the second network node (2, 3). In response to occurrence of a predetermined event, including an indication bit in the CCMs (11), which are sent on the monitored network path (7, 8) for a predetermined first period of time after the occurrence of the predetermined event, the indication bit indicates presence of a mismatch information element (13ad) in the CCM (11) that includes the indication bit. The mismatch information element (13a-d) includes information that specifies, for each protection group that the monitored network path is a member of, traffic status of a working network path and of a protection network path of the protection group.
Patent NZ-603470-A (NZ)
Title: A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
Inventor: SONNE METTE RYDAHL
IPC: A61K47/06
Filed: 2011-06-10
Abstract: Disclosed is a sprayable, storage stable, substantially anhydrous topical composition comprising a therapeutically effective amount of a vitamin D derivative or analogue and a therapeutically effective amount of a corticosteroid, the vitamin D derivative or analogue and the corticosteroid being dissolved in a pharmaceutically acceptable propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethyl ether or a propellant mixture comprising a first propellant selected from the group consisting of dimethyl ether, diethyl ether and methylethyl ether and a second propellant selected from the group consisting of C3-5 alkanes, hydrofluoroalkanes, hydrochloroalkanes, fluoroalkanes and chlorofluoroalkanes the composition further comprising a pharmaceutically acceptable lipid carrier solubilized or suspended in said propellant or propellant mixture, the lipid carrier comprising one or more lipids which on application on skin and evaporation of the propellant form a semi-solid and occlusive layer at the site of application.